Shoichi Nagamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shoichi Nagamoto has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Akihiro Yano
Department of Urology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
1 shared publication - Masahiro Arai
Department of Urology, Saitama Medical Center, Saitama Medical University, 1981, Kamoda, Kawagoe 350-8550, Saitama, Japan
1 shared publication - Morihiro Higashi
Department of Pathology, Saitama Medical University, Saitama Medical Center, Kawagoe, Saitama, Japan
1 shared publication - Sachi Kitayama
Department of Urology, Saitama Medical Center, Saitama Medical University, 1981, Kamoda, Kawagoe 350-8550, Saitama, Japan
1 shared publication - Takahisa Yamashita
Department of Pathology Saitama Medical Center, Saitama Medical University Kawagoe Japan
1 shared publication
Latest Publications
- Open Access
Metabolic and Molecular Mechanisms of Gemcitabine Resistance in Urothelial Carcinoma
Gemcitabine-based chemotherapy has long served as a standard treatment for urothelial carcinoma (UC), particularly in perioperative and metastatic settings. However, therapeutic efficacy is frequently limited by intrinsic or acquired resistance. Gemcitabine functions as a prodrug whose activity depends on coordinated processes involving cellular uptake, intracellular activation, metabolic inactivation, and nucleotide metabolism. Increasing evidence suggests that resistance in UC is mediated by multiple interconnected mechanisms beyond alterations in gemcitabine transport, activation, and inactivation alone. Key molecular determinants include human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), cytidine deaminase (CDA), and ribonucleotide reductase regulatory subunit M1 (RRM1), which is involved in nucleotide pool maintenance and DNA synthesis. In addition, replication stress responses, apoptosis evasion pathways, and tumor microenvironment-associated factors also contribute to gemcitabine resistance. Stress-adaptive pathways involving Y-box binding protein 1 (YB-1), hypoxia-inducible factor-1 alpha (HIF-1α), and autophagy-related mechanisms may further promote survival under chemotherapy-induced stress conditions. In addition, extracellular mucin-associated mechanisms may alter intratumoral drug accessibility and contribute to resistance. In this review, we summarize UC-specific evidence regarding gemcitabine resistance and discuss how these pathways collectively shape an integrated resistant phenotype.
Open AccessMetabolic and Molecular Mechanisms of Gemcitabine Resistance in Urothelial Carcinoma
Gemcitabine-based chemotherapy has long served as a standard treatment for urothelial carcinoma (UC), particularly in perioperative and metastatic settings. However, therapeutic efficacy is frequently limited by intrinsic or acquired resistance. Gemcitabine functions as a prodrug whose activity depends on coordinated processes involving cellular uptake, intracellular activation, metabolic inactivation, and nucleotide metabolism. Increasing evidence suggests that resistance in UC is mediated by multiple interconnected mechanisms beyond alterations in gemcitabine transport, activation, and inactivation alone. Key molecular determinants include human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), cytidine deaminase (CDA), and ribonucleotide reductase regulatory subunit M1 (RRM1), which is involved in nucleotide pool maintenance and DNA synthesis. In addition, replication stress responses, apoptosis evasion pathways, and tumor microenvironment-associated factors also contribute to gemcitabine resistance. Stress-adaptive pathways involving Y-box binding protein 1 (YB-1), hypoxia-inducible factor-1 alpha (HIF-1α), and autophagy-related mechanisms may further promote survival under chemotherapy-induced stress conditions. In addition, extracellular mucin-associated mechanisms may alter intratumoral drug accessibility and contribute to resistance. In this review, we summarize UC-specific evidence regarding gemcitabine resistance and discuss how these pathways collectively shape an integrated resistant phenotype.